最新临床试验：阿替唑单抗治疗复发BCG无反应性非肌肉浸润性膀胱癌

这是经美国国家癌症研究所NCI批准的一项多中心随机对照 II期临床试验，目的是研究阿替唑单抗治疗非肌肉侵袭性膀胱癌患者的疗效；这些患者已经复发，但对卡介苗（BCG）治疗无反应。单克隆抗体的免疫治疗，如阿替唑单抗，可能有助于机体免疫系统攻击癌症，并可能干扰肿瘤细胞的生长和扩散能力。

该临床试验在全美261家医院进行开展。

This phase II trial studies how well atezolizumab works in treating patients with non-muscle invasive bladder cancer that has come back and has not responded to treatment with Bacillus Calmette-Guerin (BCG). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Trial IDs